text: Super cool! Re: mitigating resistance, I’ve always found it curious that while CRBN seems to be readily lost in cell lines via CRISPR screens we have not seen LOF mutations in CRBN with lenalidomide in the context of myeloma. There are anecdotal cases and maybe some evidence for reduced expression.